Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative adjuvant sintilimab in esophageal squamous cell carcinoma
ChiCTR2100049784Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: 1-year recurrence-free survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100049784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049784.